RD Biomed is planning to launch a study in China to assess the effectiveness of its Peptest, a diagnostic device for reflux disease.
The study will include the recruitment of 1,020 participants from 10 gastroenterology departments of hospitals in Shanghai and Beijing. In the study, participants will be divided into three groups — erosive reflux disease, non-erosive reflux disease and control.
The study will examine the sensitivity in each of these groups and the efficacy of Peptest for diagnosing reflux.
More articles on GI/endoscopy:
Dr. Amar Naik joins Loyola University Health System
AGA to hold workshop on effective scope cleaning
15 gastroenterologist CEOs